Skip to search formSkip to main contentSkip to account menu

ofatumumab

Known as: Ofatumumabum, immunoglobulin G1, anti-(human CD20 (antigen))(human monoclonal humax-CD20 heavy chain), disulfide with human monoclonal humax-CD20 kappa-chain, dimer 
A fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity… 
National Institutes of Health

Related topics

Related topics

10 relations
50 ML ofatumumab 20 MG/ML Injection [Arzerra]B-LymphocytesHuMax-CD20Human B-Lymphocyte Antigen CD20, human

Broader (2)

Antineoplastic AgentsMonoclonal Antibodies

Narrower (1)

Arzerra

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Author response: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study
On behalf of all authors, we thank Dr. Kearney for the comment on our article.1 The reported “90% reduction in gadolinium… 
2018
2018
Affinity maturation and characterization of the ofatumumab monoclonal antibody
CD20 molecule, a phosphoprotein with 297 amino acids and four transmembrane domains, is a member of MS4A protein family. Anti… 
Review
2016
Review
2016
New monoclonal antibodies for the treatment of acute lymphoblastic leukemia.
Review
2014
Review
2014
Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III).
The most significant data presented at the 28th Congress of the European Committee for Treatment and Research in Multiple… 
2014
2014
The MIRROR Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Investigate the Safety and MRI Efficacy of Subcutaneous Ofatumumab in Subjects with Relapsing…
OBJECTIVE: To determine the effects of distinct ofatumumab dosing regimens compared to placebo on cumulative number of new brain… 
2014
2014
Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis
Ofatumumab is a human monoclonal antibody directed at CD20 approved for treatment of chronic lymphocytic leukemia. The population… 
Review
2014
Review
2014
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928)
Background: Salvage chemoimmunotherapy, followed by high-dose therapy and autologous stem cell transplantation (ASCT) for… 
Review
2010
Review
2010
Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia
Abstract 921 Background: Patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab (FA-ref) or… 
Review
2010
Review
2010
Ofatumumab Monotherapy for Treatment of Patients with Relapsed/Progressive Diffuse Large B-Cell Lymphoma: Results From a Multicenter Phase II Study
Abstract 3955 Background: Patients (pts) with relapsed diffuse large B-cell lymphoma (DLBCL) ineligible for autologous stem cell… 
Review
2010
Review
2010
Ofatumumab, a human anti-CD20 monoclonal antibody.
IMPORTANCE OF THE FIELD Since relapse of chronic lymphocytic leukemia (CLL), and refractoriness to treatment following relapse… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)